Lenox Advisors Appoints Angie LeMar Chief Strategy Officer
LeMar will drive strategic enhancements to advance company growth and Lenox Advisors' 'Clients for Life'
approach
"Angie's well-earned promotion is an opportunity for her to drive growth through strategic, company-wide initiatives that align with our guiding principles," said
For the past two decades, LeMar has held various management positions at Lenox Advisors, and will maintain her current responsibilities of leading the company's national Lenox Executive Benefits business strategy, including the expansion of the firm's corporate capabilities and business development activities. In addition, LeMar will continue to oversee teams that support individual life and disability solutions.
"Angie's new role reflects Lenox Advisors' focus on tackling industry challenges and adapting to evolving client needs and changes in the wealth management sector," added Large. "I'm excited to see Angie's impact on our business and the value we deliver to clients."
About Lenox Advisors
Driven by the notion of what is best for you, Lenox Advisors builds custom solutions that integrate the financial needs of emerging affluent and other individuals with high net worth, their families, and corporate clients. As your advocate, we take the time to deeply understand your goals and values, informing our dynamic strategies to help protect and preserve your wealth. To learn more, visit www.lenoxadvisors.com.
About NFP
NFP, an Aon company, is an organization of consultative advisors and problem solvers helping companies and individuals address their most significant risk, workforce, wealth management and retirement challenges. We are more than 7,700 colleagues in the US,
MEDIA CONTACT:
[email protected]
917-865-5791
View original content to download multimedia:https://www.prnewswire.com/news-releases/lenox-advisors-appoints-angie-lemar-chief-strategy-officer-302389444.html
SOURCE Lenox Advisors
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
- In HelloNation, Real Estate Experts Josh Meacham & Anthony Marangon Discuss What Buyers Notice About Show Low Homes & Cabins
- W. Scott Stornetta, a Founding Father of Blockchain, Joins SafeBets as Chair of the Advisory Council
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share